Vimarsana
Biggest News Aggregation in the World

Willfully Infringed News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Willfully Infringed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Willfully Infringed Today - Breaking & Trending Today

10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies - Vimarsana News

10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies

10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies

10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies - Vimarsana News

10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies

/PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that a jury in the U.S. District Court for the...

10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies - Vimarsana News

10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies

Jury Awards 10x Genomics Over $31 Million in Damages and Finds All Seven Asserted Patents Valid and Willfully Infringed by NanoString GeoMx Decision is Third Ruling Against NanoString, Showing...

Other Barks & Bites for Friday, June 23: FTC Asks Appeals Court to Reconsider Pharma Antitrust Case; U.S. Ambassador Warns of China IP Theft; Patent Reform Bills Introduced - Vimarsana News

Other Barks & Bites for Friday, June 23: FTC Asks Appeals Court to Reconsider Pharma Antitrust Case; U.S. Ambassador Warns of China IP Theft; Patent Reform Bills Introduced

This week in Other Barks & Bites: the FTC files an amicus brief asking an appeals court to reconsider an antitrust case against pharmaceutical companies who paid generic manufacturers to drop their patent disputes; senators introduce a bill that would eliminate judicial exceptions to patent eligibility; and more.